DE60111622T2 - Getrennte dosis therapien mit gefässschädigender aktivität - Google Patents
Getrennte dosis therapien mit gefässschädigender aktivität Download PDFInfo
- Publication number
- DE60111622T2 DE60111622T2 DE60111622T DE60111622T DE60111622T2 DE 60111622 T2 DE60111622 T2 DE 60111622T2 DE 60111622 T DE60111622 T DE 60111622T DE 60111622 T DE60111622 T DE 60111622T DE 60111622 T2 DE60111622 T2 DE 60111622T2
- Authority
- DE
- Germany
- Prior art keywords
- hours
- vascular damaging
- use according
- doses
- vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0007740 | 2000-03-31 | ||
GB0007740A GB0007740D0 (en) | 2000-03-31 | 2000-03-31 | Combination therapy |
GB0013928A GB0013928D0 (en) | 2000-06-08 | 2000-06-08 | Methods of treatment |
GB0013928 | 2000-06-08 | ||
GB0014904A GB0014904D0 (en) | 2000-06-20 | 2000-06-20 | Methods of treatment |
GB0014904 | 2000-06-20 | ||
PCT/GB2001/001329 WO2001074369A1 (en) | 2000-03-31 | 2001-03-27 | Divided dose therapies with vascular damaging activity |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60111622D1 DE60111622D1 (de) | 2005-07-28 |
DE60111622T2 true DE60111622T2 (de) | 2006-05-18 |
Family
ID=27255635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60111622T Expired - Fee Related DE60111622T2 (de) | 2000-03-31 | 2001-03-27 | Getrennte dosis therapien mit gefässschädigender aktivität |
Country Status (23)
Country | Link |
---|---|
US (1) | US20030055024A1 (et) |
EP (1) | EP1272200B1 (et) |
JP (1) | JP2003528921A (et) |
KR (1) | KR20020084267A (et) |
CN (1) | CN1422157A (et) |
AT (1) | ATE298240T1 (et) |
AU (2) | AU4258601A (et) |
BR (1) | BR0109671A (et) |
CA (1) | CA2402078A1 (et) |
CZ (1) | CZ20023231A3 (et) |
DE (1) | DE60111622T2 (et) |
EE (1) | EE200200549A (et) |
ES (1) | ES2243466T3 (et) |
HU (1) | HUP0300576A3 (et) |
IL (1) | IL151627A0 (et) |
IS (1) | IS6555A (et) |
MX (1) | MXPA02009603A (et) |
NO (1) | NO20024683L (et) |
NZ (1) | NZ534190A (et) |
PL (1) | PL357282A1 (et) |
PT (1) | PT1272200E (et) |
SK (1) | SK13902002A3 (et) |
WO (1) | WO2001074369A1 (et) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE200200565A (et) | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
GB0223379D0 (en) * | 2002-10-09 | 2002-11-13 | Angiogene Pharm Ltd | Combination therapy |
FR2848212B1 (fr) * | 2002-12-06 | 2006-10-27 | Aventis Pharma Sa | Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation |
KR20060036058A (ko) * | 2003-06-18 | 2006-04-27 | 앤지오젠 파마슈티칼스 리미티드 | 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5fu,cpt-11 또는 5-fu 및 cpt-11과 함께 zd6126을포함하는 조성물 |
GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI830078L (fi) * | 1982-01-15 | 1983-07-16 | Lilly Co Eli | Askorbinsyraetrar och liknande foereningar |
US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
AU6605690A (en) * | 1989-10-27 | 1991-05-31 | Du Pont Merck Pharmaceutical Company, The | Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity |
CA2078214C (en) * | 1990-04-02 | 1995-03-28 | Robert Lee Dow | Benzylphosphonic acid tyrosine kinase inhibitors |
CA2108889A1 (en) * | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
JPH11228594A (ja) * | 1998-02-16 | 1999-08-24 | Meiji Milk Prod Co Ltd | 新規プロゲステロン化合物 |
AU5717400A (en) * | 1999-06-14 | 2001-01-02 | Cancer Research Ventures Limited | Cancer therapy |
US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
-
2001
- 2001-03-27 EE EEP200200549A patent/EE200200549A/et unknown
- 2001-03-27 DE DE60111622T patent/DE60111622T2/de not_active Expired - Fee Related
- 2001-03-27 AT AT01915495T patent/ATE298240T1/de not_active IP Right Cessation
- 2001-03-27 IL IL15162701A patent/IL151627A0/xx unknown
- 2001-03-27 PT PT01915495T patent/PT1272200E/pt unknown
- 2001-03-27 PL PL01357282A patent/PL357282A1/xx not_active Application Discontinuation
- 2001-03-27 NZ NZ534190A patent/NZ534190A/en unknown
- 2001-03-27 AU AU4258601A patent/AU4258601A/xx active Pending
- 2001-03-27 CN CN01807663A patent/CN1422157A/zh active Pending
- 2001-03-27 CA CA002402078A patent/CA2402078A1/en not_active Abandoned
- 2001-03-27 AU AU2001242586A patent/AU2001242586B2/en not_active Ceased
- 2001-03-27 KR KR1020027012915A patent/KR20020084267A/ko not_active Application Discontinuation
- 2001-03-27 BR BR0109671-0A patent/BR0109671A/pt not_active IP Right Cessation
- 2001-03-27 EP EP01915495A patent/EP1272200B1/en not_active Expired - Lifetime
- 2001-03-27 HU HU0300576A patent/HUP0300576A3/hu unknown
- 2001-03-27 US US10/239,898 patent/US20030055024A1/en not_active Abandoned
- 2001-03-27 SK SK1390-2002A patent/SK13902002A3/sk unknown
- 2001-03-27 CZ CZ20023231A patent/CZ20023231A3/cs unknown
- 2001-03-27 WO PCT/GB2001/001329 patent/WO2001074369A1/en not_active Application Discontinuation
- 2001-03-27 JP JP2001572112A patent/JP2003528921A/ja active Pending
- 2001-03-27 ES ES01915495T patent/ES2243466T3/es not_active Expired - Lifetime
- 2001-03-27 MX MXPA02009603A patent/MXPA02009603A/es unknown
-
2002
- 2002-09-19 IS IS6555A patent/IS6555A/is unknown
- 2002-09-30 NO NO20024683A patent/NO20024683L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CZ20023231A3 (cs) | 2003-01-15 |
CA2402078A1 (en) | 2001-10-11 |
IS6555A (is) | 2002-10-18 |
AU2001242586B2 (en) | 2004-12-16 |
DE60111622D1 (de) | 2005-07-28 |
JP2003528921A (ja) | 2003-09-30 |
NO20024683L (no) | 2002-10-15 |
CN1422157A (zh) | 2003-06-04 |
BR0109671A (pt) | 2003-02-04 |
ES2243466T3 (es) | 2005-12-01 |
HUP0300576A3 (en) | 2005-02-28 |
SK13902002A3 (sk) | 2003-05-02 |
WO2001074369A1 (en) | 2001-10-11 |
IL151627A0 (en) | 2003-04-10 |
US20030055024A1 (en) | 2003-03-20 |
MXPA02009603A (es) | 2004-05-14 |
EE200200549A (et) | 2004-02-16 |
NZ534190A (en) | 2007-05-31 |
NO20024683D0 (no) | 2002-09-30 |
EP1272200A1 (en) | 2003-01-08 |
PL357282A1 (en) | 2004-07-26 |
PT1272200E (pt) | 2005-09-30 |
AU4258601A (en) | 2001-10-15 |
KR20020084267A (ko) | 2002-11-04 |
ATE298240T1 (de) | 2005-07-15 |
HUP0300576A2 (hu) | 2003-07-28 |
EP1272200B1 (en) | 2005-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60108489T2 (de) | Kombinationstherapien mit gefässschädigender aktivität | |
DE60017878T2 (de) | Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind | |
EP0359981B1 (de) | Pharmazeutische Kombinationspräparate und deren Verwendung als antineoplastische Arzneimittel | |
DE60311788T2 (de) | Kombinationstherapie zur behandlung von krebs | |
DE60111622T2 (de) | Getrennte dosis therapien mit gefässschädigender aktivität | |
DE69911350T2 (de) | Vorbeugung und behandlung einer durch einen immunschwächevirus ausgelösten infektion | |
EP2015743A2 (de) | Glutadon | |
DE3323264C2 (de) | Arzneimittel zur Behandlung von vaskulären Erkrankungen | |
EP1633394B1 (de) | Pharmazeutische kombinationspräparate zur krebstherapie enthaltend glutaminase und antineoplastische anthracycline oder platinverbindungen | |
EP0285906B1 (de) | Wirkstoff zur Tumorbekämpfung | |
AT412447B (de) | Mittel mit zerstörender wirkung auf maligne tumore sowie verfahren zu seiner herstellung | |
AU2001242586A1 (en) | Divided dose therapies with vascular damaging activity | |
EP1524273A1 (de) | Verfahren zur Herstellung von trans- oder cis-Diammoniumdichlorodihydroxoplatin (IV)-Salzen und -Derivaten und ihre Verwendung zur Herstellung von pharmazeutischen Wirkstoffen | |
DE2460756A1 (de) | Arzneimittel zur verbesserung der endogenen prostaglandinbildung sowie neue n-(pyridylalkyl)-benzamide, die als wirkstoffe fuer die arzneimittel geeignet sind, und verfahren zu deren herstellung | |
RU2279277C2 (ru) | Лечение разделенными дозами агентов с сосудоразрушающей активностью | |
DE60308403T2 (de) | Kombinationstherapie mit gemzitabin und zd6126 | |
AT408837B (de) | Verwendung von caroverin und/oder caroverin. hydrochlorid zur herstellung von als antioxidantien wirkenden zusammensetzungen und/oder von neuroregenerativen zusammensetzungen | |
US2775539A (en) | Process of and compositions for combating epileptic seizures with atrolactamide | |
CH694549A5 (de) | Verwendung einer synergistischen Zusammensetzung, die Ascorbat und Lysin für Zustände enthält zur Behandlung extrazellularer Matrixdegeration. | |
DE2401449A1 (de) | Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen | |
US20070021392A1 (en) | Divided dose therapies with vascular damaging activity | |
ZA200207108B (en) | Divided dose therapies with vascular damaging activity. | |
EP0834309A2 (de) | Verwendung einer Liposomenlösung zur Verstärkung der Wirksamkeit und/oder Verminderung der Toxizität von Arzneimitteln |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |